解放军医学杂志2024，Vol.49Issue(2)：220-228,9.DOI:10.11855/j.issn.0577-7402.1986.2023.0524
新抗原脉冲树突状细胞疫苗在肿瘤免疫治疗中的作用
Advances in the study of neoantigen pulsed dendritic cell vaccines in tumor immunotherapy
摘要
Abstract
Neoantigen pulsed dendritic cell vaccine(Neo-DCVac)is a new type of tumor immunotherapy.Neoantigen is strong immunologic and tumor-specific mutated peptides expressed in a tumor.Neo-DCVac is a therapeutic modality based on the uptake and processing of neoantigens by dendritic cells and their delivery and activation of T cells to trigger the body's immune response for anti-tumor effects.The development of individualized Neo-DCVac based on high-throughput sequencing is expected to be a new direction for precision immunotherapy of tumors.In this review,we discuss construction of individualized Neo-DCVac,clinical application of combination therapy in solid tumors,suitable population for vaccination and the current limitations of Neo-DCVac,aiming to provide a theoretical reference for research on tumor immunotherapy.关键词
新抗原/树突状细胞疫苗/肿瘤/免疫治疗Key words
neoantigen/dendritic cell vaccine/tumor/immunotherapy分类
医药卫生引用本文复制引用
王彤昕,张凡,闫鑫,张雅婷,李玉民..新抗原脉冲树突状细胞疫苗在肿瘤免疫治疗中的作用[J].解放军医学杂志,2024,49(2):220-228,9.基金项目
This work was supported by the National Natural Science Foundation of China(31770537),and the Grand Scientific and Technological Project of Gansu Province(20ZD7FA003) 国家自然科学基金(31770537) （31770537）
甘肃省重大科技项目(20ZD7FA003) （20ZD7FA003）
